Leucine improves the aerosol performance of dry powder inhaler formulations of siRNA-loaded nanoparticles

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Leucine improves the aerosol performance of dry powder inhaler formulations of siRNA-loaded nanoparticles. / Xu, You; Harinck, Laure; Lokras, Abhijeet G; Gerde, Per; Selg, Ewa; Sjöberg, Carl-Olof; Franzyk, Henrik; Thakur, Aneesh; Foged, Camilla.

In: International Journal of Pharmaceutics, Vol. 621, 121758, 2022.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Xu, Y, Harinck, L, Lokras, AG, Gerde, P, Selg, E, Sjöberg, C-O, Franzyk, H, Thakur, A & Foged, C 2022, 'Leucine improves the aerosol performance of dry powder inhaler formulations of siRNA-loaded nanoparticles', International Journal of Pharmaceutics, vol. 621, 121758. https://doi.org/10.1016/j.ijpharm.2022.121758

APA

Xu, Y., Harinck, L., Lokras, A. G., Gerde, P., Selg, E., Sjöberg, C-O., Franzyk, H., Thakur, A., & Foged, C. (2022). Leucine improves the aerosol performance of dry powder inhaler formulations of siRNA-loaded nanoparticles. International Journal of Pharmaceutics, 621, [121758]. https://doi.org/10.1016/j.ijpharm.2022.121758

Vancouver

Xu Y, Harinck L, Lokras AG, Gerde P, Selg E, Sjöberg C-O et al. Leucine improves the aerosol performance of dry powder inhaler formulations of siRNA-loaded nanoparticles. International Journal of Pharmaceutics. 2022;621. 121758. https://doi.org/10.1016/j.ijpharm.2022.121758

Author

Xu, You ; Harinck, Laure ; Lokras, Abhijeet G ; Gerde, Per ; Selg, Ewa ; Sjöberg, Carl-Olof ; Franzyk, Henrik ; Thakur, Aneesh ; Foged, Camilla. / Leucine improves the aerosol performance of dry powder inhaler formulations of siRNA-loaded nanoparticles. In: International Journal of Pharmaceutics. 2022 ; Vol. 621.

Bibtex

@article{a74af5ae97694138aea55d6f7870c6c3,
title = "Leucine improves the aerosol performance of dry powder inhaler formulations of siRNA-loaded nanoparticles",
abstract = "Thermostable dry powder inhaler (DPI) formulations with high aerosol performance are attractive inhalable solid dosage forms for local treatment of inflammatory lung diseases. We recently demonstrated that lipidoid-polymer hybrid nanoparticles (LPNs) loaded with small interfering RNA (siRNA) directed against tumor necrosis factor alpha (TNF-α) mediate efficient intracellular siRNA delivery and reduce inflammation in vivo. Here, we show that mixtures of the stabilizing excipients trehalose (Tre) and dextran (Dex), in combination with the shell-forming dispersion enhancer leucine (Leu), stabilize TNF-α siRNA-loaded LPNs during spray drying into nanocomposite microparticles (DPI formulations), and result in DPI formulations with high aerosol performance. At low Leu content (0 to 10%, w/w), the DPI formulations were amorphous, and exhibited poor aerosol performance. When the Leu content was increased from 20 to 60% (w/w), the surface content of Leu increased from 39.2 to 68.1 mol%, and the flowability was significantly improved. Microscopy analyses suggest that the improved powder dispersibility is the result of a wrinkled surface morphology, which reduces the surface area available for interparticle interactions. Increasing the Leu content further (above 10%, w/w) did not influence the aerosol performance, and the aerosol yield was maximal at 30-40% Leu (w/w). Formulations containing 40% Leu and a Tre:Dex ratio of 10:90 (w/w) displayed a high fine particle fraction and aerosol properties suitable for inhalation. The chemical integrity of TNF-α siRNA was preserved in the solid state, and biodistribution studies in mice showed that pulmonary administration of DPI formulations with high aerosol performance resulted in homogenous deep lung deposition. Our results demonstrate that at optimal ratios, ternary excipient mixtures of Leu, Tre and Dex protect TNF-α siRNA-loaded LPNs during spray drying. Hence, this study shows that microparticles with an amorphous Tre/Dex matrix and a crystalline Leu shell are required for stabilizing the nanocomposite LPNs in the solid state, and for ensuring aerosol properties suitable for inhalation.",
author = "You Xu and Laure Harinck and Lokras, {Abhijeet G} and Per Gerde and Ewa Selg and Carl-Olof Sj{\"o}berg and Henrik Franzyk and Aneesh Thakur and Camilla Foged",
note = "Copyright {\textcopyright} 2022. Published by Elsevier B.V.",
year = "2022",
doi = "10.1016/j.ijpharm.2022.121758",
language = "English",
volume = "621",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Leucine improves the aerosol performance of dry powder inhaler formulations of siRNA-loaded nanoparticles

AU - Xu, You

AU - Harinck, Laure

AU - Lokras, Abhijeet G

AU - Gerde, Per

AU - Selg, Ewa

AU - Sjöberg, Carl-Olof

AU - Franzyk, Henrik

AU - Thakur, Aneesh

AU - Foged, Camilla

N1 - Copyright © 2022. Published by Elsevier B.V.

PY - 2022

Y1 - 2022

N2 - Thermostable dry powder inhaler (DPI) formulations with high aerosol performance are attractive inhalable solid dosage forms for local treatment of inflammatory lung diseases. We recently demonstrated that lipidoid-polymer hybrid nanoparticles (LPNs) loaded with small interfering RNA (siRNA) directed against tumor necrosis factor alpha (TNF-α) mediate efficient intracellular siRNA delivery and reduce inflammation in vivo. Here, we show that mixtures of the stabilizing excipients trehalose (Tre) and dextran (Dex), in combination with the shell-forming dispersion enhancer leucine (Leu), stabilize TNF-α siRNA-loaded LPNs during spray drying into nanocomposite microparticles (DPI formulations), and result in DPI formulations with high aerosol performance. At low Leu content (0 to 10%, w/w), the DPI formulations were amorphous, and exhibited poor aerosol performance. When the Leu content was increased from 20 to 60% (w/w), the surface content of Leu increased from 39.2 to 68.1 mol%, and the flowability was significantly improved. Microscopy analyses suggest that the improved powder dispersibility is the result of a wrinkled surface morphology, which reduces the surface area available for interparticle interactions. Increasing the Leu content further (above 10%, w/w) did not influence the aerosol performance, and the aerosol yield was maximal at 30-40% Leu (w/w). Formulations containing 40% Leu and a Tre:Dex ratio of 10:90 (w/w) displayed a high fine particle fraction and aerosol properties suitable for inhalation. The chemical integrity of TNF-α siRNA was preserved in the solid state, and biodistribution studies in mice showed that pulmonary administration of DPI formulations with high aerosol performance resulted in homogenous deep lung deposition. Our results demonstrate that at optimal ratios, ternary excipient mixtures of Leu, Tre and Dex protect TNF-α siRNA-loaded LPNs during spray drying. Hence, this study shows that microparticles with an amorphous Tre/Dex matrix and a crystalline Leu shell are required for stabilizing the nanocomposite LPNs in the solid state, and for ensuring aerosol properties suitable for inhalation.

AB - Thermostable dry powder inhaler (DPI) formulations with high aerosol performance are attractive inhalable solid dosage forms for local treatment of inflammatory lung diseases. We recently demonstrated that lipidoid-polymer hybrid nanoparticles (LPNs) loaded with small interfering RNA (siRNA) directed against tumor necrosis factor alpha (TNF-α) mediate efficient intracellular siRNA delivery and reduce inflammation in vivo. Here, we show that mixtures of the stabilizing excipients trehalose (Tre) and dextran (Dex), in combination with the shell-forming dispersion enhancer leucine (Leu), stabilize TNF-α siRNA-loaded LPNs during spray drying into nanocomposite microparticles (DPI formulations), and result in DPI formulations with high aerosol performance. At low Leu content (0 to 10%, w/w), the DPI formulations were amorphous, and exhibited poor aerosol performance. When the Leu content was increased from 20 to 60% (w/w), the surface content of Leu increased from 39.2 to 68.1 mol%, and the flowability was significantly improved. Microscopy analyses suggest that the improved powder dispersibility is the result of a wrinkled surface morphology, which reduces the surface area available for interparticle interactions. Increasing the Leu content further (above 10%, w/w) did not influence the aerosol performance, and the aerosol yield was maximal at 30-40% Leu (w/w). Formulations containing 40% Leu and a Tre:Dex ratio of 10:90 (w/w) displayed a high fine particle fraction and aerosol properties suitable for inhalation. The chemical integrity of TNF-α siRNA was preserved in the solid state, and biodistribution studies in mice showed that pulmonary administration of DPI formulations with high aerosol performance resulted in homogenous deep lung deposition. Our results demonstrate that at optimal ratios, ternary excipient mixtures of Leu, Tre and Dex protect TNF-α siRNA-loaded LPNs during spray drying. Hence, this study shows that microparticles with an amorphous Tre/Dex matrix and a crystalline Leu shell are required for stabilizing the nanocomposite LPNs in the solid state, and for ensuring aerosol properties suitable for inhalation.

U2 - 10.1016/j.ijpharm.2022.121758

DO - 10.1016/j.ijpharm.2022.121758

M3 - Journal article

C2 - 35483619

VL - 621

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

M1 - 121758

ER -

ID: 304877064